Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc.'s Q·Score is 5.8/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. 76% of 29 covering analysts have a positive rating. Key area to monitor: currently unprofitable (-11% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for GILD is $157.41, based on ratings from 27 Wall Street analysts. This is 7.7% above the current price of $146.12. Price targets are forward-looking estimates and not guarantees of future performance.

Gilead Sciences, Inc. (GILD) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 14.8×. The consensus analyst price target of $157.41 is 8% above the current price.

Gilead Sciences, Inc.'s next earnings report is expected on approximately October 29, 2026.

Gilead Sciences, Inc. has a net profit margin of -10.6%, indicating the company is currently operating at a net loss. Its gross margin stands at 79.6%, indicating a high-margin business model.

Gilead Sciences, Inc. currently offers a dividend yield of 2.24%, which is above the typical market average dividend yield. Dividend yields can change based on price movements and company payout decisions.

Gilead Sciences, Inc. is reporting solid revenue growth of 10.2% year-over-year.

Gilead Sciences, Inc. has a debt-to-equity ratio of 2.23×, reflecting a high debt-to-equity ratio, which increases financial risk especially in rising rate environments. Its current ratio is 1.26×, suggesting it should be monitored for near-term liquidity.